{"id":23879,"date":"2024-12-03T10:00:00","date_gmt":"2024-12-03T15:00:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=23879"},"modified":"2026-04-08T16:26:06","modified_gmt":"2026-04-08T20:26:06","slug":"common-reasons-for-drug-patent-rejections-and-solutions","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/common-reasons-for-drug-patent-rejections-and-solutions\/","title":{"rendered":"Why Drug Patent Applications Fail: The Rejection Playbook Every Pharma IP Team Needs"},"content":{"rendered":"\n

How to diagnose the six most common grounds for pharmaceutical patent rejection \u2014 and the prosecution strategies that actually reverse them.<\/em><\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>\n\n\n\n

The USPTO issued a final rejection on Amgen’s most commercially critical patent portfolio in 2023. The Supreme Court upheld it unanimously. Amgen’s Repatha franchise \u2014 a blockbuster PCSK9 inhibitor generating roughly $1.6 billion in annual revenue \u2014 lost protection not because a competitor found a better molecule, but because Amgen’s patent lawyers wrote claims that were too broad for the specification to support. The rejection, in its essence, came down to a four-word problem: not enough working examples.<\/p>\n\n\n\n

That outcome cost Amgen years of litigation expense, created an opening for Sanofi and Regeneron, and sent a warning across every major biologics program globally. It was not unique. Drug patent rejections at the USPTO, the European Patent Office (EPO), and the Japan Patent Office (JPO) follow predictable patterns \u2014 patterns that sophisticated IP teams can anticipate, prepare for, and in most cases prevent.<\/p>\n\n\n\n

This guide documents those patterns with specificity. It covers the six primary grounds on which pharmaceutical patent applications fail, the statistical profile of each, the case law that defines how examiners apply them, and the prosecution tactics that have the highest documented success rates for overcoming them. Where relevant, it references DrugPatentWatch \u2014 the pharmaceutical patent intelligence platform used by competitive intelligence teams, IP counsel, and investment analysts to map patent landscapes and track prosecution histories in real time.<\/p>\n\n\n\n

The goal is simple: give pharma IP teams, business development leads, and institutional investors the information they need to treat patent prosecution as the revenue-protection function it actually is.<\/p>\n\n\n\n

\n\n\n\n

Part I: The Rejection Landscape<\/strong><\/h2>\n\n\n\n
\n\n\n\n

Why Pharmaceutical Patent Prosecution Is Harder Than You Think<\/strong><\/h2>\n\n\n\n

The standard argument for pharmaceutical patents is well-established. Drug development costs exceed $2.6 billion per approved compound when accounting for failures across the pipeline [2]. Development timelines from IND filing to NDA approval average more than a decade. Without the temporary market exclusivity that a patent provides \u2014 nominally 20 years from filing, often shorter in effective life \u2014 the economics of drug development collapse. No rational private actor spends $2.6 billion to produce a molecule that a competitor can copy on day one of approval.<\/p>\n\n\n\n

Patent offices understand this logic. They also know that pharmaceutical companies understand the leverage that patent protection provides, and they examine pharmaceutical applications accordingly. The rate of substantive rejection in this sector runs higher than in many other technology categories, the legal standards are applied with specific nuance to chemistry and biology, and the post-grant challenge environment \u2014 particularly Inter Partes Review (IPR) at the PTAB \u2014 is more adversarial than most sectors face.<\/p>\n\n\n\n

Approximately 50% of all patent applications are rejected based on prior art findings at some stage of prosecution [12]. For pharmaceutical applications specifically, that number is compounded by the complexity of the chemistry involved, the depth of the prior art record in any major therapeutic area, and the frequency with which incremental innovations \u2014 new forms, new formulations, new dosing regimens \u2014 are exactly what examiners scrutinize hardest. <blockquote> “The number of pharmaceutical patent term extension requests at the USPTO accounts for approximately 40% of all such requests, reflecting the unique regulatory timelines of drug development. The average extension granted is around 2.5 years in the U.S., 3 years in the EU, and 2 years in Japan \u2014 partial compensation for development time already consumed.” \u2014 PatentPC, *Patent Term Extension Statistics: What Innovators Need to Know* [69] <\/blockquote><\/p>\n\n\n\n

The practical implication: by the time a drug reaches FDA approval and enters market exclusivity, its patent clock has often been running for eight to twelve years. What begins as a 20-year grant frequently delivers ten years or fewer of real commercial protection. Each rejection that extends prosecution time further compresses that window.<\/p>\n\n\n\n

This is not an abstract legal problem. It is a revenue problem, and it should be managed like one.<\/p>\n\n\n\n

\n\n\n\n

The Six Rejection Grounds That Drive the Most Pharmaceutical Attrition<\/strong><\/h2>\n\n\n\n

Patent offices in the U.S., Europe, and Japan reject pharmaceutical applications on a relatively consistent set of statutory grounds. The legal labels differ by jurisdiction \u2014 35 U.S.C. \u00a7 102 at the USPTO corresponds to Article 54 of the European Patent Convention (EPC), for instance \u2014 but the underlying patentability concepts are largely harmonized. Six grounds account for the overwhelming majority of pharmaceutical patent rejections:<\/p>\n\n\n\n

    \n
  1. Lack of novelty (anticipation)<\/li>\n\n\n\n
  2. Obviousness \/ lack of inventive step<\/li>\n\n\n\n
  3. Insufficient written description<\/li>\n\n\n\n
  4. Lack of enablement<\/li>\n\n\n\n
  5. Lack of utility \/ industrial applicability<\/li>\n\n\n\n
  6. Patent-ineligible subject matter and indefiniteness<\/li>\n<\/ol>\n\n\n\n

    Each operates differently, demands a different prosecution response, and carries different statistical odds of reversal. The sections below address each in turn.<\/p>\n\n\n\n

    \n\n\n\n

    Rejection Ground #1: Lack of Novelty<\/strong><\/h2>\n\n\n\n

    What ‘Novelty’ Actually Means in Practice<\/strong><\/h3>\n\n\n\n

    Under 35 U.S.C. \u00a7 102 (post-AIA), an invention lacks novelty if a single prior art reference discloses every element of the claimed invention [8]. The standard is strict: a rejection requires anticipation by one reference, not a combination. Every element of the claim must be present, expressly or inherently, in that single reference.<\/p>\n\n\n\n

    For pharmaceutical applicants, the prior art universe is enormous. Drug discovery operates in scientific fields with decades of published literature. A compound synthesized in 1987 and described in a German journal that was never commercialized can still anticipate a claim filed today. Under the AIA’s first-inventor-to-file system, prior art includes global disclosures \u2014 a paper published in a Chinese journal, a conference abstract, or even a publicly accessible database entry [8].<\/p>\n\n\n\n

    Anticipation rejections under \u00a7 102 are more common in early prosecution than they are fatal in the long run. Data consistently shows that more than 70% of applications that receive a \u00a7 102 rejection eventually reach allowance with a proper prosecution strategy [16]. The more important question is how long that process takes and what scope is surrendered along the way.<\/p>\n\n\n\n

    The Polymorph Problem: Inherent Anticipation<\/strong><\/h3>\n\n\n\n

    Polymorphism \u2014 the ability of a solid chemical compound to exist in more than one crystalline form \u2014 is one of the most commercially important and legally contested areas of pharmaceutical patent law. Different polymorphic forms of the same active pharmaceutical ingredient (API) can have meaningfully different dissolution rates, bioavailability profiles, stability characteristics, and processing properties. From a product development standpoint, the ‘right’ polymorph can be the difference between a drug that works and one that doesn’t.<\/p>\n\n\n\n

    Patenting a polymorph, however, requires clearing a novelty hurdle that is higher than it looks. The core problem is inherent anticipation: if a prior art reference describes a synthesis process that would inevitably produce the claimed polymorph \u2014 even if the prior art never explicitly characterized the crystal form \u2014 the examiner can argue that the polymorph was inherently disclosed [14].<\/p>\n\n\n\n

    The burden that follows is non-trivial. The applicant must demonstrate that the prior art process would not inevitably produce the claimed form. This often requires experimental data comparing the outcomes of different synthetic routes, sometimes including crystallographic characterization data that was not generated until well after the priority date. At the European Patent Office, polymorph claims face the additional requirement of establishing a ‘technical effect’ beyond what was known \u2014 a heightened inventive step standard built into how the EPO applies Article 54 and Article 56 together [14].<\/p>\n\n\n\n

    The strategic implication is that polymorph patent applications should never be filed without prior art synthesis data that establishes the specific conditions under which the claimed form \u2014 and not competing forms \u2014 is reliably produced. A claim to Form I that cannot be distinguished from what prior art routes would produce is a claim that will receive a \u00a7 102 rejection with high probability.<\/p>\n\n\n\n

    Case Study: Novartis v. Union of India and the Efficacy Threshold<\/strong><\/h3>\n\n\n\n

    The Novartis v. Union of India<\/em> Supreme Court decision from 2013 remains the most cited global example of novelty-adjacent pharmaceutical patent rejection, though its precise legal basis was India’s Section 3(d) rather than a classical anticipation ground [15]. Novartis sought protection for the beta-crystalline form of imatinib mesylate \u2014 the active compound in Gleevec \u2014 which it characterized as demonstrating improved bioavailability compared to earlier-known amorphous imatinib.<\/p>\n\n\n\n

    India’s Supreme Court rejected the application on the ground that the improved bioavailability did not constitute a significant difference in therapeutic efficacy as required by Section 3(d), which was specifically designed to prevent the patenting of incremental modifications of known substances without demonstrated therapeutic improvement [15]. The court drew a distinction between a property (bioavailability) and an outcome (efficacy in treating patients) that many applicants in markets with similar provisions still underestimate.<\/p>\n\n\n\n

    What the Novartis case illustrates for global IP strategy is this: the legal standard for ‘newness’ in pharmaceuticals varies not just by jurisdiction but by how each jurisdiction defines what kind of improvement counts. In India, enhanced bioavailability in a rat model does not satisfy the standard. In the U.S., the same data might support a non-obviousness argument around unexpected results. Applicants filing in multiple jurisdictions need country-specific prosecution strategies, not a single global specification transplanted across markets.<\/p>\n\n\n\n

    Strategies for Overcoming \u00a7 102 Rejections<\/strong><\/h3>\n\n\n\n

    When an anticipation rejection arrives, the most effective single response \u2014 documented at a 67.6% success rate \u2014 is an examiner interview [53]. Interviews allow the applicant’s counsel to understand precisely which elements of the claim the examiner believes are disclosed by which passages of the cited reference, and to address those points directly rather than through written argument alone.<\/p>\n\n\n\n

    Beyond interviews, the core prosecution options for \u00a7 102 rejections are:<\/p>\n\n\n\n

    Distinguishing the prior art:<\/strong> Arguments demonstrating that the cited reference does not actually disclose one or more claim elements \u2014 either because the examiner misread the reference or because the reference discloses a structurally or functionally distinct compound or process.<\/p>\n\n\n\n

    Claim amendment:<\/strong> Adding a limitation from the dependent claims or the specification that the prior art does not teach. The risk here is prosecution history estoppel \u2014 any limitation added to distinguish prior art becomes a permanent boundary on claim scope in subsequent infringement litigation.<\/p>\n\n\n\n

    Evidence of non-inherency:<\/strong> Experimental data showing that the process described in the prior art would not inevitably produce the claimed compound or form, which is particularly relevant for polymorph claims facing inherent anticipation arguments.<\/p>\n\n\n\n

    Anticipation rejections are also reversed at PTAB appeal at a higher rate than obviousness rejections [16], which makes appeal a more viable option when the examiner’s reading of the prior art is genuinely indefensible.<\/p>\n\n\n\n

    \n\n\n\n

    Rejection Ground #2: Obviousness<\/strong><\/h2>\n\n\n\n

    The Standard and Why It’s the Hardest Ground to Clear<\/strong><\/h3>\n\n\n\n

    Obviousness is consistently the most common rejection ground at the USPTO, the EPO, and the JPO, and it is the rejection that pharmaceutical applicants find hardest to reverse with certainty [53]. Under 35 U.S.C. \u00a7 103, a claim is obvious if the differences between the claimed invention and the prior art would have been apparent to a person having ordinary skill in the art (POSITA) at the time the invention was made. The EPO’s equivalent standard \u2014 lack of inventive step under Article 56 of the EPC \u2014 applies the ‘problem-solution approach,’ which asks whether the claimed invention addresses a technical problem in a non-obvious way relative to the closest prior art.<\/p>\n\n\n\n

    Both standards require a fact-intensive analysis of what was known, what a skilled person would have been motivated to do, and whether there was a reasonable expectation of success. The last element is where pharmaceutical prosecution gets difficult. Drug development is, by definition, a field where chemists test modifications to known structures with some expectation that certain modifications will produce certain results. That is what medicinal chemistry is. Examiners who want to find obviousness in pharmaceutical applications have a rich supply of logic to draw on.<\/p>\n\n\n\n

    The KSR Effect on Pharmaceutical Patent Prosecution<\/strong><\/h3>\n\n\n\n

    The Supreme Court’s 2007 decision in KSR International Co. v. Teleflex Inc.<\/em> fundamentally changed how obviousness is assessed at the USPTO [19]. Before KSR<\/em>, the dominant framework was the ‘teaching, suggestion, or motivation’ (TSM) test \u2014 to reject a claim as obvious, an examiner needed to identify a specific reason in the prior art why a POSITA would have combined the cited references. KSR<\/em> rejected the rigidity of this approach and held that courts and examiners should use a flexible, expansive analysis that includes common sense, ordinary creativity, and the ‘obvious to try’ doctrine.<\/p>\n\n\n\n

    The practical consequence for pharmaceutical patents was immediate and quantifiable. Studies published in BMC Bioinformatics<\/em> found that the proportion of obviousness rulings at the Federal Circuit increased following KSR<\/em> [21]. The ‘obvious to try’ doctrine \u2014 which holds that a claim is obvious if a POSITA would have had a finite number of identified, predictable solutions to try \u2014 became a standard examiner tool for rejecting drug compound claims, formulation claims, and dosing regimen claims.<\/p>\n\n\n\n

    The ‘obvious to try’ doctrine presents a particular problem in pharmaceutical research because the process of drug development often involves systematic screening of a defined chemical space. If you know that modifying a specific functional group on a known scaffold tends to improve selectivity, and you test a dozen variants of that modification, the one that works can be characterized by an examiner as the product of an obvious, finite search. The fact that the researcher did not know in advance which variant would work \u2014 or whether any would \u2014 is harder to establish in prosecution than it should be.<\/p>\n\n\n\n

    The Dosing Regimen Battle: Obviousness Applied to Method Claims<\/strong><\/h3>\n\n\n\n

    Method of treatment claims \u2014 including dosing regimen patents \u2014 represent one of the highest-value and most contested categories of pharmaceutical patent [28]. These claims do not protect a molecule or a formulation; they protect the specific way a known drug is used. For branded pharmaceutical companies, they are often a last line of defense once composition and formulation patents expire.<\/p>\n\n\n\n

    Examiners approach dosing regimen claims with particular skepticism. If a drug is known, and clinical practice has established a dose range, and the claimed regimen falls within that range or follows a logical extrapolation from known pharmacokinetic data, the examiner can and typically does argue that adjusting dose frequency or amount is ‘routine optimization’ rather than invention.<\/p>\n\n\n\n

    The Federal Circuit, however, has pushed back on this characterization in specific cases. In Janssen Pharmaceuticals, Inc. v. Mylan Laboratories<\/em>, decided in 2025, the Federal Circuit upheld a pharmaceutical dosing claim as non-obvious despite prior art describing dosing regimens for the same active ingredient [27]. The determinative factor was the combination of valsartan and sacubitril: at the priority date, sacubitril had never been administered to humans, and related compounds in its class had shown discouraging results in clinical studies. The court found no basis for a ‘reasonable expectation of success’ that would justify an obvious-to-try rejection [27].<\/p>\n\n\n\n

    This decision matters because it establishes a clear evidentiary standard for overcoming obviousness in dosing regimen cases: the applicant must demonstrate either that the outcome was not predictable from the prior art, or that the prior art actively discouraged the pursued approach, or both. ‘Discouraging results’ in related compounds is explicitly recognized as a factor that negates the motivation to combine.<\/p>\n\n\n\n

    Earlier, in Genentech v. Sandoz<\/em>, the outcome was the opposite: adjusting drug doses was found to be a routine clinical practice that a POSITA would undertake without inventive step [31]. The difference between the two outcomes comes down to specificity \u2014 how specific was the proposed modification, and how predictable was the result?<\/p>\n\n\n\n

    Secondary Considerations: The Applicant’s Most Reliable Defense<\/strong><\/h3>\n\n\n\n

    The most reliable prosecution strategy for overcoming obviousness rejections in pharmaceutical applications is evidence of secondary considerations (also called ‘objective indicia of non-obviousness’). These include:<\/p>\n\n\n\n

    Unexpected results:<\/strong> Pharmacological data showing that the claimed compound or formulation exhibits properties that a POSITA would not have predicted based on the prior art. This is the most powerful form of evidence and requires comparative experimental data against the closest prior art compound or formulation.<\/p>\n\n\n\n

    Long-felt but unresolved need:<\/strong> Evidence that the problem the invention solves was recognized in the literature for years before the applicant’s filing date, and that despite the problem’s known importance, no one had solved it.<\/p>\n\n\n\n

    Commercial success:<\/strong> Sales data demonstrating that the invention has achieved market success, combined with a nexus showing that the success results from the claimed invention rather than from marketing or other non-inventive factors.<\/p>\n\n\n\n

    Skepticism of experts:<\/strong> Documented statements from scientists or clinicians who expressed doubt that the claimed approach would work, made before the invention’s success was known.<\/p>\n\n\n\n

    Of these, unexpected results carry the most weight at the USPTO and EPO because they are the most directly connected to the statutory non-obviousness inquiry. An applicant who can show through rigorous comparative data that their compound performs in a way that the prior art art would not have suggested \u2014 whether in potency, selectivity, half-life, solubility, or side-effect profile \u2014 has built the strongest possible record for overcoming an obviousness rejection and for defending the patent in subsequent IPR or litigation.<\/p>\n\n\n\n

    The key practical point: this data needs to be generated before the application is filed, or at minimum before examination reaches a critical stage. Data submitted late in prosecution can feel like reverse engineering the argument to fit the rejection, and examiners treat it that way.<\/p>\n\n\n\n

    The In re Bell and In re Deuel Standard for Biotechnology<\/strong><\/h3>\n\n\n\n

    Before leaving the obviousness discussion, it is worth addressing the specific application of \u00a7 103 to DNA sequence claims \u2014 a category that remains commercially relevant for therapeutic gene products, siRNA therapeutics, and diagnostics.<\/p>\n\n\n\n

    In In re Bell<\/em> and the subsequent In re Deuel<\/em>, the courts established that knowing a protein’s amino acid sequence does not automatically make the gene encoding that protein obvious, because the degeneracy of the genetic code means that a vast number of nucleotide sequences could theoretically encode the same amino acid sequence [19]. Without a specific reason to select the particular nucleotide sequence claimed, an obvious-to-try rejection is not supported.<\/p>\n\n\n\n

    This line of reasoning has limits \u2014 particularly where computational tools can now predict gene sequences with increasing reliability \u2014 but it remains a viable argument for applicants who can demonstrate that the specific sequence they claim was not predictable from the protein structure alone.<\/p>\n\n\n\n

    \n\n\n\n

    Rejection Ground #3: Insufficient Written Description<\/strong><\/h2>\n\n\n\n

    What Possession Actually Means<\/strong><\/h3>\n\n\n\n

    The written description requirement under 35 U.S.C. \u00a7 112(a) is distinct from enablement, though the two are often confused and frequently rejected together. Written description requires that the specification demonstrate the inventor was in ‘possession’ of the claimed invention at the time of filing [33]. This is not a formal possession concept \u2014 it does not mean the inventor had a sample in hand. It means the specification must describe the claimed invention in sufficient structural or functional detail that a reader skilled in the art would recognize that the inventor actually conceived of what is being claimed.<\/p>\n\n\n\n

    The possession requirement creates a specific problem for pharmaceutical applicants who file early to secure priority dates and then amend or broaden claims during prosecution. If the original specification does not describe the broader claimed subject matter, the amended claims lack written description support \u2014 regardless of how meritorious the underlying science is.<\/p>\n\n\n\n

    A canonical failure mode is the ‘negative limitation’ problem. In ICU Medical, Inc. v. Alaris Medical Systems<\/em>, the Federal Circuit invalidated claims to a medical valve that omitted a ‘spike’ component \u2014 a spikeless valve \u2014 because the original specification described valves that all had spikes [38]. The written description requirement prevented the applicant from claiming a version of the device that the original disclosure did not contemplate.<\/p>\n\n\n\n

    In Novozymes A\/S v. DuPont Nutrition Biosciences APS<\/em>, the court found that even though individual claim limitations were described in the specification, the specific combination of those limitations as claimed was not [38]. This ‘claim-as-combined’ standard is particularly demanding for pharmaceutical applications involving multi-component claims \u2014 co-formulations, combination therapies, or compounds with multiple functional characteristics.<\/p>\n\n\n\n

    The Amgen Problem: Broad Functional Claims and the Enablement Convergence<\/strong><\/h3>\n\n\n\n

    The Supreme Court’s 2023 decision in Amgen Inc. v. Sanofi<\/em> is the most consequential pharmaceutical patent ruling of the decade, and its implications are still being processed by IP teams across the biologics sector [35].<\/p>\n\n\n\n

    Amgen’s patents claimed an entire genus of antibodies defined by their function \u2014 specifically, antibodies that bind to PCSK9 and block its binding to the LDL receptor. The patents disclosed 26 specific working antibodies out of what Amgen acknowledged was an astronomically large universe of possible antibodies that could meet the functional definition [35]. The Court held unanimously that this was insufficient enablement: if you claim the full genus, you must enable the full genus.<\/p>\n\n\n\n

    The decision fused written description and enablement concerns into a single practical standard for biologics applicants: the scope of what you claim must correspond to the scope of what you have actually made and characterized. Broad functional claims \u2014 ‘any antibody that achieves X result’ \u2014 are now presumptively suspect unless the specification provides either a structural correlation (a conserved binding region, a defined scaffold) or enough diverse working examples to allow a POSITA to extrapolate across the claimed genus without undue experimentation [36].<\/p>\n\n\n\n

    The downstream effect on biologic drug patent strategy has been substantial. Companies are now forced to choose between claiming broadly and risking enablement rejection, or claiming narrowly around characterized antibodies and accepting a more limited scope of protection. Neither is ideal. The practical response being adopted by leading IP teams is to file continuation applications as additional antibodies are characterized, building portfolio breadth over time rather than trying to capture it in a single broad claim at the outset.<\/p>\n\n\n\n

    The Novartis Entresto Reversal: Later-Arising Technology<\/strong><\/h3>\n\n\n\n

    Not all written description news from the Federal Circuit has gone against applicants. In Novartis v. Torrent Pharma Inc.<\/em>, a 2025 Federal Circuit decision reversed a lower court’s finding of lack of written description for Novartis’s Entresto (sacubitril\/valsartan) patent [32]. The district court had found that ‘complexes’ of valsartan and sacubitril were not adequately described because such complexes were unknown at the priority date. The Federal Circuit disagreed, clarifying that later-arising technology does not need to have been described in the specification \u2014 what matters is whether the specification, as written, is broad enough to encompass the later-characterized form [32].<\/p>\n\n\n\n

    This is a meaningful carve-out. It means pharmaceutical applicants are not required to anticipate every future characterization of their compounds in the original specification. Claims written at a sufficient level of generality can legitimately cover forms that were only characterized after filing, as long as the specification does not affirmatively exclude those forms and a skilled reader would recognize them as falling within the described invention.<\/p>\n\n\n\n

    Practical Drafting Implications<\/strong><\/h3>\n\n\n\n

    The written description standard points toward a set of specific drafting practices that reduce the risk of \u00a7 112(a) rejection:<\/p>\n\n\n\n

    The specification should describe multiple working examples, not a single preferred embodiment. For small molecule drugs, this means characterized analogs. For biologics, it means multiple sequenced and tested antibodies, variants, or constructs. For formulations, it means multiple characterized compositions across the claimed parameter ranges.<\/p>\n\n\n\n

    Claims should be drafted at multiple levels of scope \u2014 broad, intermediate, and narrow \u2014 with each level supported by corresponding disclosure in the specification. If the broad claim fails enablement, the intermediate or narrow claims should survive.<\/p>\n\n\n\n

    Functional claim language should, wherever possible, be paired with structural correlates. ‘An antibody that binds to PCSK9 with an IC50 of less than 1 nM, wherein the antibody comprises a heavy chain variable region having at least 90% sequence identity to SEQ ID NO: X’ is harder to reject than ‘an antibody that blocks PCSK9.’<\/p>\n\n\n\n

    \n\n\n\n

    Rejection Ground #4: Lack of Enablement<\/strong><\/h2>\n\n\n\n

    The ‘Undue Experimentation’ Standard<\/strong><\/h3>\n\n\n\n

    Enablement under 35 U.S.C. \u00a7 112(a) requires that the patent specification teach a person skilled in the art how to make and use the claimed invention without undue experimentation [1]. The ‘undue experimentation’ inquiry is not binary \u2014 some experimentation is always expected and permitted. The question is whether the amount of work required to practice the full scope of the claim exceeds what a skilled practitioner would reasonably undertake.<\/p>\n\n\n\n

    The USPTO examiner bears the initial burden of establishing a reasonable basis to doubt enablement. Once that threshold is met, the burden shifts to the applicant to provide data demonstrating that the claimed scope is enabled [35].<\/p>\n\n\n\n

    The factors that inform the undue experimentation analysis \u2014 known as the Wands<\/em> factors after the 1988 Federal Circuit case \u2014 include: the breadth of the claims; the nature of the invention; the state of the prior art; the level of ordinary skill in the art; the level of predictability in the art; whether the specification provides working examples; the quantity of experimentation needed; and the extent to which the specification provides specific guidance [35].<\/p>\n\n\n\n

    Pharmaceutical and biotechnology applications are particularly vulnerable to enablement rejection because they operate in fields where predictability is inherently limited. A medicinal chemist cannot, in general, predict with certainty whether a modification to a lead compound will improve potency or kill it. A protein engineer cannot guarantee that a single amino acid substitution will maintain function. When claims are written at a level of generality that encompasses both the configurations that work and the many more that don’t, the question becomes whether the specification’s working examples provide sufficient guidance to locate the working configurations without exhaustive trial and error.<\/p>\n\n\n\n

    Strategies for \u00a7 112(a) Compliance<\/strong><\/h3>\n\n\n\n

    The enablement challenge is primarily addressed through data, not argument. Post-filing experimental data is accepted by the USPTO to support enablement claims, but it must be submitted at the right time in prosecution and framed correctly [22]. Declarations under 37 CFR 1.132 submitted with experimental results comparing the claimed invention to prior art have been recognized by the USPTO as material evidence that examiners must consider when assessing both non-obviousness and enablement [22].<\/p>\n\n\n\n

    For biological claims, the practical strategy that has emerged post-Amgen<\/em> is to characterize as many working examples as possible before filing, specifically including examples from across the claimed structural or functional space. If you claim an antibody genus defined by function, you want examples that cover diverse epitope contacts, diverse heavy chain CDR sequences, and diverse expression systems \u2014 enough that a skilled reader would not need to reinvent a screening program to find additional working examples.<\/p>\n\n\n\n

    For small molecule claims with broad genus scope, SAR (structure-activity relationship) data covering multiple points in the claimed chemical space is the most effective support. An examiner who sees SAR data across a 40-compound matrix is looking at evidence that the claimed genus has been genuinely explored, not simply asserted.<\/p>\n\n\n\n

    \n\n\n\n

    Rejection Ground #5: Utility and Patent-Ineligible Subject Matter<\/strong><\/h2>\n\n\n\n

    The Utility Baseline and When It Becomes a Problem<\/strong><\/h3>\n\n\n\n

    For most pharmaceutical compounds, the utility requirement \u2014 35 U.S.C. \u00a7 101 (utility prong) \u2014 is straightforward. A compound with demonstrated in vitro activity against a disease target, or with established in vivo efficacy in an animal model, satisfies the ‘credible, specific and substantial’ utility standard [8]. Utility rejections are relatively uncommon in small molecule pharmaceutical prosecution compared to the other grounds discussed here.<\/p>\n\n\n\n

    They become relevant in two specific contexts. First, early-stage compounds with only in silico activity predictions and no experimental data face utility rejections because computational predictions alone do not establish that a compound ‘works’ for a stated purpose. Second, diagnostic method claims can face utility challenges where the claimed diagnostic marker correlates statistically with a condition but the mechanism linking the marker to the condition is unclear.<\/p>\n\n\n\n

    In both contexts, the solution is the same: experimental data. Pharmacological activity data, dose-response curves, and animal model results all support utility. The practical point is that pharmaceutical patent applications should not be filed on purely computational or theoretical predictions without at least some preliminary experimental validation.<\/p>\n\n\n\n

    Patent-Ineligible Subject Matter: The \u00a7 101 Problem for Diagnostics and AI<\/strong><\/h3>\n\n\n\n

    The \u00a7 101 patent eligibility requirement \u2014 separate from the \u00a7 101 utility analysis \u2014 has become one of the most disruptive forces in pharmaceutical IP since the Supreme Court’s decisions in Mayo Collaborative Services v. Prometheus Laboratories<\/em> (2012) and Alice Corp. v. CLS Bank International<\/em> (2014) [1]. Under the Mayo\/Alice<\/em> framework, claims directed to laws of nature, natural phenomena, or abstract ideas are patent-ineligible unless they include an ‘inventive concept’ that transforms the claim into something significantly more than merely stating the judicial exception.<\/p>\n\n\n\n

    For pharmaceutical diagnostics \u2014 a category that includes companion diagnostic tests, biomarker assays, and pharmacogenomic methods \u2014 Mayo<\/em> created a near-existential problem. Diagnostic method claims typically follow the structure: ‘administering a drug or obtaining a sample; measuring a level of X; correlating the level to a condition or outcome.’ The Mayo<\/em> Court held that this structure merely applies a natural correlation (the relationship between a biomarker and a disease state) without adding meaningful inventive content, and therefore is not patent-eligible [1].<\/p>\n\n\n\n

    The practical effect has been substantial. Companies developing precision medicine diagnostics face a \u00a7 101 landscape in which the most valuable commercial claims \u2014 ‘if biomarker level is above Y, then use drug Z’ \u2014 are the most legally vulnerable. Prosecution strategy in this space now requires framing diagnostic claims as specific technical improvements to measurement methods rather than as applications of natural correlations. Claims directed to specific assay improvements, novel sample processing steps, or machine learning methods with specific technical implementations have better \u00a7 101 survival odds than naked correlation claims.<\/p>\n\n\n\n

    For AI-related pharmaceutical patents \u2014 drug-target identification, de novo drug design, clinical trial optimization \u2014 the \u00a7 101 problem is similar. AI is frequently characterized by examiners as an implementation of a mathematical model (an abstract idea), and AI-patent applications face initial rejection rates of 25-40% under \u00a7 101 [41]. Successful prosecution requires drafting claims that tie the AI method to a specific technical application: not ‘a method for predicting drug-receptor binding using a neural network’ but ‘a method for generating a three-dimensional pharmacophore model using a convolutional neural network trained on [specific data], wherein the model outputs a binding affinity score that directs synthesis of a defined chemical class.’<\/p>\n\n\n\n

    The specificity of the technical implementation, and the connection between that implementation and a concrete technological result, is what separates \u00a7 101-eligible AI claims from those that fail on abstract idea grounds.<\/p>\n\n\n\n

    \n\n\n\n

    Rejection Ground #6: Indefiniteness<\/strong><\/h2>\n\n\n\n

    What Examiners Mean When They Say a Claim Is ‘Indefinite’<\/strong><\/h3>\n\n\n\n

    A claim is indefinite under 35 U.S.C. \u00a7 112(b) if it does not ‘particularly point out and distinctly claim’ the subject matter of the invention [43]. In practice, indefiniteness rejections in pharmaceutical prosecution arise in predictable categories:<\/p>\n\n\n\n

    Functional claim language without adequate structural correlation (‘an effective amount,’ ‘a therapeutically effective dose,’ or ‘a pharmaceutically acceptable carrier’ can all be challenged if the specification does not provide sufficient guidance on what these terms mean in the context of the claimed invention).<\/p>\n\n\n\n

    Polymorph claims that specify crystallographic peaks without adequate precision \u2014 if a polymorph claim identifies characteristic X-ray powder diffraction (XRPD) peaks without specifying the wavelength used or the measurement conditions, an examiner can reject the claim as indefinite because the claim scope cannot be determined without that information [14].<\/p>\n\n\n\n

    Measurement-based limitations where the measurement method is not standardized or is not specified in the claim or specification.<\/p>\n\n\n\n

    Relative terms \u2014 ‘substantially,’ ‘about,’ ‘approximately’ \u2014 where the specification does not provide sufficient anchoring context for a skilled artisan to know what ranges or variations are encompassed.<\/p>\n\n\n\n

    Why Indefiniteness Rejections Are More Consequential Than They Appear<\/strong><\/h3>\n\n\n\n

    Indefiniteness rejections are often characterized in prosecution as ‘minor’ or ‘formal’ issues, but they deserve more respect than that. A \u00a7 112(b) rejection that cannot be resolved without adding new matter \u2014 information not present in the original specification \u2014 forces the applicant to either narrow the claim to a scope that the existing specification supports or abandon the broader claim scope entirely.<\/p>\n\n\n\n

    The downstream risk is in litigation. An issued patent with indefinite claim terms is vulnerable to invalidity challenge on \u00a7 112(b) grounds at PTAB or in district court. The Supreme Court’s 2014 decision in Nautilus, Inc. v. Biosig Instruments, Inc.<\/em> established that a claim is indefinite when it fails to inform a skilled artisan of the scope of the invention with ‘reasonable certainty’ [43]. That standard, while rejecting both the pre-Nautilus<\/em> ‘insolubly ambiguous’ test and an overly demanding precision requirement, leaves significant room for post-grant indefiniteness challenges that pharmaceutical defendants exploit routinely.<\/p>\n\n\n\n

    The practical lesson: indefiniteness should be resolved during prosecution with precision, not papered over with broad argument. If a measurement condition needs to be specified, specify it. If ‘about’ needs a numerical range to anchor it, provide the range in the specification before filing.<\/p>\n\n\n\n

    \n\n\n\n

    Part II: The Data<\/strong><\/h2>\n\n\n\n
    \n\n\n\n

    Rejection and Grant Rates Across Major Jurisdictions<\/strong><\/h2>\n\n\n\n

    Understanding the statistical landscape of pharmaceutical patent examination matters for resource allocation, timeline modeling, and portfolio valuation. The numbers across the three major jurisdictions reveal both the challenge and the opportunity.<\/p>\n\n\n\n

    USPTO: The Baseline and What It Obscures<\/strong><\/h3>\n\n\n\n

    The USPTO’s overall patent grant rate \u2014 across all technology categories \u2014 has recently hovered between 75% and 80% [58]. This headline figure obscures a more granular reality for pharmaceutical applicants. The average time from filing to grant in pharmaceutical patent cases ranges from 3.4 to 4.4 years [2], and that figure does not capture the full range of complex biologics cases that take longer.<\/p>\n\n\n\n

    A more actionable statistic: 48% of applications that received final rejections in January 2024 ultimately issued as patents or received a notice of allowance within one year [59]. A final rejection at the USPTO is not, by itself, a terminal outcome. Post-final practice \u2014 including after-final amendments, Requests for Continued Examination (RCEs), and examiner interviews \u2014 provides multiple avenues for continued prosecution.<\/p>\n\n\n\n

    The PTAB invalidates claims at a rate that should concern any pharmaceutical IP team building a defense strategy around issued patents. Between 2019 and 2024, the all-claims invalidation rate at PTAB rose from 55% to 70% [65]. That is the rate at which petitioned proceedings result in complete invalidation of all challenged claims. The rate of any-claim invalidation is higher.<\/p>\n\n\n\n

    The notable exception to this grim PTAB picture involves Orange Book patents specifically. Pharmaceutical patents listed in the FDA’s Orange Book demonstrate a meaningfully better survival profile in IPR proceedings: 50% survive with no claims invalidated, and 83% survive unscathed \u2014 meaning they emerge from the IPR proceeding with all challenged claims intact [66]. This compares favorably to the less-than-20% no-invalidation rate for non-pharmaceutical patents facing IPR [66]. The explanation is both that Orange Book patents are prosecuted with greater rigor \u2014 knowing they will face Hatch-Waxman challenges \u2014 and that pharmaceutical patentees invest more heavily in IPR defense when market exclusivity is directly at stake.<\/p>\n\n\n\n

    EPO: Stricter Disclosure, Active Post-Grant Challenges<\/strong><\/h3>\n\n\n\n

    The EPO received over 190,000 patent applications in 2023, with a grant rate of 68% \u2014 notably lower than the USPTO’s general grant rate [60]. The EPO rejected 15% of all applications outright in 2023, with novelty, inventive step, and insufficient disclosure as the leading grounds [60]. The average time from application to grant was 32 months in 2023 [60].<\/p>\n\n\n\n

    What distinguishes EPO practice from USPTO practice for pharmaceutical applicants is the post-grant opposition system. Approximately 20% of granted EPO patents faced opposition in 2023 [60]. Opposition proceedings at the EPO allow any third party to challenge a granted patent on virtually all grounds within nine months of grant. For high-value pharmaceutical patents, opposition is nearly certain \u2014 generic manufacturers, biosimilar developers, and competing innovators all monitor EPO grants in relevant therapeutic areas and file oppositions systematically.<\/p>\n\n\n\n

    EPO oppositions are meaningfully different from PTAB IPRs: the procedural rules, the claim amendment opportunities, and the grounds for challenge differ in ways that require jurisdiction-specific expertise. European pharmaceutical patent holders who have not engaged European patent litigation counsel well in advance of likely opposition dates are unprepared for the fight.<\/p>\n\n\n\n

    JPO: Speed and a High Grant Rate<\/strong><\/h3>\n\n\n\n

    The JPO processed approximately 290,000 patent applications in 2022 and reported a first-action pendency of just 9.4 months in fiscal year 2023 [62, 64]. The JPO’s grant rate is high relative to the USPTO and EPO, driven partly by Japan’s examination standards and partly by the JPO’s stated commitment to fast, high-quality examination [63].<\/p>\n\n\n\n

    For pharmaceutical applicants, JPO practice requires attention to the Japanese requirement for experimental data supporting utility and efficacy. The JPO tends to require pharmacological data demonstrating that a claimed compound or formulation actually works for its stated purpose. Applications that rely on structural analogy arguments without supporting biological activity data face more difficulty in Japan than in the U.S.<\/p>\n\n\n\n

    Post-grant, the JPO saw an invalidation rate of approximately 20.9% for challenged patents between 2017 and 2021 [62] \u2014 lower than the PTAB’s rate, reflecting both the higher bar for post-grant challenges in Japan and the different legal standards applied.<\/p>\n\n\n\n

    Summary Statistics<\/strong><\/h3>\n\n\n\n
    Metric<\/th>USPTO<\/th>EPO<\/th>JPO<\/th><\/tr><\/thead>
    Overall Grant Rate<\/td>75-80% [58]<\/td>68% (2023) [60]<\/td>High (not publicly standardized) [62]<\/td><\/tr>
    Average Time to First Action \/ Grant<\/td>3.4-4.4 years to grant [2]<\/td>32 months to grant (2023) [60]<\/td>9.4 months to first action (FY2023) [64]<\/td><\/tr>
    \u00a7 102 Allowance Rate After Rejection<\/td>>70% proceed to allowance [16]<\/td>N\/A (comparable novelty standard)<\/td>N\/A<\/td><\/tr>
    PTAB \/ Post-Grant Invalidation Rate<\/td>60-70% of challenged claims [31]<\/td>~20% of granted patents opposed [60]<\/td>~20.9% invalidated (2017-2021) [62]<\/td><\/tr>
    Orange Book Patent IPR Survival<\/td>50% with no claims invalidated [66]<\/td>N\/A<\/td>N\/A<\/td><\/tr>
    \u00a7 102 Interview Success Rate<\/td>67.6% [53]<\/td>N\/A<\/td>N\/A<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
    \n\n\n\n

    Part III: The Prosecution Playbook<\/strong><\/h2>\n\n\n\n
    \n\n\n\n

    Pre-Filing Strategy: How Rejection-Resistant Applications Get Built<\/strong><\/h2>\n\n\n\n

    Prior Art Search as a Business Intelligence Function<\/strong><\/h3>\n\n\n\n

    The most expensive patent prosecution mistake a pharmaceutical company can make is discovering blocking prior art after a patent application has been filed. At that point, the options are all costly: narrowing claims through amendment, abandoning the application, or fighting an anticipation rejection through prosecution and potentially appeal.<\/p>\n\n\n\n

    The alternative is a comprehensive pre-filing prior art search that treats patent searching as a business intelligence function rather than a legal checkbox. A serious prior art search for a new pharmaceutical compound covers:<\/p>\n\n\n\n

    Issued patents and published applications at the USPTO, EPO, JPO, WIPO, and key national offices including China (CNIPA), India, and Canada. Chemical compound searches should include structural analogs at multiple levels of similarity \u2014 not just the specific compound claimed but structurally related compounds that could render the claimed compound obvious.<\/p>\n\n\n\n

    Non-patent literature including journal articles, conference abstracts, clinical trial registrations, and FDA regulatory filings. In pharmaceutical chemistry, the most dangerous prior art is often not a patent \u2014 it is a 2009 paper from a German academic lab that synthesized a structurally similar compound for a completely different purpose.<\/p>\n\n\n\n

    Commercial databases including CAS SciFinder, Reaxys, and Derwent Innovation, which provide chemical structure searching capabilities that general patent search tools do not.<\/p>\n\n\n\n

    Platforms like DrugPatentWatch provide pharmaceutical-specific patent intelligence that goes beyond standard patent search tools. DrugPatentWatch aggregates Orange Book patent data, tracks patent expiration timelines, monitors prosecution histories across jurisdictions, and maps patent coverage for specific drugs and drug classes. For a pre-filing search in a competitive therapeutic area, knowing which competitors have already claimed which structural classes \u2014 and when those claims expire \u2014 is as important as knowing what the prior art discloses. DrugPatentWatch’s landscape analysis capabilities let IP teams identify white space in a patent thicket before they commit to a filing strategy.<\/p>\n\n\n\n

    The ‘File Early, Search Comprehensively’ Principle<\/strong><\/h3>\n\n\n\n

    These two objectives \u2014 filing early to secure priority and searching comprehensively to avoid prior art problems \u2014 are in tension with each other. Provisional patent applications resolve this tension by providing a 12-month window between the initial priority filing and the full nonprovisional application.<\/p>\n\n\n\n

    A well-structured provisional application secures the priority date with as much data as is available at that moment, while the 12-month pendency period is used to conduct the comprehensive prior art search, generate additional experimental data, and draft claims with full awareness of the prior art landscape. This approach is both the standard practice of leading pharmaceutical IP departments and the most cost-effective way to build a prosecution strategy that anticipates rather than reacts to examiner objections.<\/p>\n\n\n\n

    The ‘file often’ component of this principle refers to continuation applications \u2014 both continuations and continuations-in-part \u2014 which allow applicants to present additional claim scope based on new data developed during the R&D process [16]. A drug that generates new clinical data post-filing \u2014 new indications, new patient populations, new dosing regimens \u2014 is a drug that should have new continuation applications capturing that data and converting it into patent protection. This is the legitimate, legally sound version of what is often pejoratively called ‘evergreening’: accumulating additional patent protection around a compound as the clinical program generates new, patentable data.<\/p>\n\n\n\n

    Claim Drafting Principles That Survive Examination<\/strong><\/h3>\n\n\n\n

    Good pharmaceutical patent claims are not written for the application as it exists on filing day. They are written for the examination that will occur two to three years later and the litigation that might occur a decade after that. This long horizon should shape every drafting decision.<\/p>\n\n\n\n

    Claim scope should be multi-layered. For a novel compound, the claim set should include: a broad genus claim defining the chemical class, intermediate claims at a useful level of structural specificity, a claim to the specific compound of interest, formulation claims, method of treatment claims, and (where appropriate) dosing regimen claims. If the genus claim fails examination, the specific compound claim should survive. If the formulation claim is challenged in litigation, the method claim provides an alternative basis for relief.<\/p>\n\n\n\n

    Experimental data should be incorporated in the specification, not just the claims. A specification that includes pharmacological activity data, comparative efficacy data against prior art compounds, and formulation stability data provides ammunition for every subsequent prosecution argument around non-obviousness and enablement. Data included in the specification at filing can be cited in arguments and declarations throughout prosecution without the procedural complications that accompany late-submitted post-filing data.<\/p>\n\n\n\n

    Language should be precise but not unnecessarily narrow. ‘A compound of Formula I’ is better than ‘the specific compound having the following structure,’ because the former covers obvious chemical variants and stereoisomers while the latter may not. ‘A pharmaceutical composition comprising a therapeutically effective amount’ is standard language with established legal meaning. Departures from established claim language should be deliberate and supported by specific strategic reasons.<\/p>\n\n\n\n

    \n\n\n\n

    Reactive Prosecution: How to Respond When Rejections Arrive<\/strong><\/h2>\n\n\n\n

    Reading an Office Action Like a Litigator, Not a Formalist<\/strong><\/h3>\n\n\n\n

    An Office Action is not a bureaucratic obstacle. It is a detailed record of how an examiner \u2014 a person with scientific training in the relevant field \u2014 has read the prior art and assessed the claims. The arguments and positions taken by the examiner in the Office Action will follow the application through its prosecution history and can be used against the patentee in infringement litigation through the doctrine of prosecution history estoppel.<\/p>\n\n\n\n

    Before responding to an Office Action, the IP team should complete four specific analytical tasks. First, identify exactly which elements of each claim the examiner believes are disclosed or rendered obvious by which passages of which cited references \u2014 this requires reading the cited references, not just the examiner’s characterization of them. Second, assess whether the examiner’s reading of the prior art is defensible \u2014 examiners make reading errors, and a well-documented argument showing that the examiner misidentified a passage is often the fastest path to allowance. Third, identify the minimum claim amendment that would distinguish the invention from the cited prior art without unnecessarily surrendering scope. Fourth, evaluate what additional experimental evidence, if any, would materially strengthen the prosecution record.<\/p>\n\n\n\n

    This analysis takes time. Rushing an Office Action response to meet the statutory deadline without completing this analysis produces the most common prosecution mistake: a response that makes arguments in the alternative \u2014 ‘the reference doesn’t disclose X, but even if it did, the claimed invention is non-obvious’ \u2014 which examiners read as a concession on the first point and a fallback position on the second.<\/p>\n\n\n\n

    Examiner Interviews: The Highest-ROI Tool in Prosecution<\/strong><\/h3>\n\n\n\n

    Examiner interviews are the most consistently effective single tactic in pharmaceutical patent prosecution. For \u00a7 102 (anticipation) rejections, they achieve a 67.6% success rate [53]. For \u00a7 112 rejections, they are the most successful single-response mechanism [44]. The mechanism is simple: interviews allow direct, real-time communication between the applicant’s counsel and the examiner, resolving misunderstandings about claim scope or prior art interpretation faster than written arguments permit.<\/p>\n\n\n\n

    The USPTO’s interview practice guidelines allow applicants to request an interview at any stage of prosecution, pre-or post-final rejection [54]. The most effective interviews follow a specific structure: the applicant submits a proposed agenda or a written interview summary in advance, identifying the specific issues to be addressed and proposing either a claim amendment or a targeted legal argument that would resolve those issues [54]. Examiners who arrive at an interview with a concrete proposed resolution on the table \u2014 rather than an open-ended discussion of patentability \u2014 are far more likely to agree to allowance.<\/p>\n\n\n\n

    One practical point that many applicants underuse: an interview conducted before filing a formal written response to an Office Action can dramatically change the analysis. If the interview reveals that the examiner has a specific additional prior art reference in mind that was not cited in the Office Action, or that the examiner’s \u00a7 103 rejection is based on a combination of references that can be distinguished by a specific claim amendment, knowing that before drafting the written response produces a sharper and more targeted argument.<\/p>\n\n\n\n

    Post-Filing Data Submissions and 37 CFR 1.132 Declarations<\/strong><\/h3>\n\n\n\n

    When an examiner questions non-obviousness, the most powerful response is experimental data demonstrating unexpected results. Under 37 CFR 1.132, applicants can submit affidavits and declarations from inventors, expert witnesses, or third parties containing evidence of criticality, unexpected results, commercial success, long-felt need, or expert skepticism [22]. The USPTO requires examiners to consider this evidence as part of the totality of the record on obviousness [22].<\/p>\n\n\n\n

    The practical limitations of post-filing data submissions are well established:<\/p>\n\n\n\n

    Data submitted very late in prosecution \u2014 after a final rejection, or after appeal \u2014 receives less weight from examiners who view it as manufactured-to-order evidence rather than contemporaneous scientific work. The earlier in prosecution that convincing data is submitted, the better.<\/p>\n\n\n\n

    The data must establish a nexus between the unexpected result and the claimed invention, not just a general improvement over some prior art compound. Comparative data \u2014 showing that the claimed compound performs materially better than the closest prior art compound under the same experimental conditions \u2014 is far more persuasive than data showing absolute performance without a proper comparator.<\/p>\n\n\n\n

    Expert declarations under 37 CFR 1.132 from recognized scientists in the relevant field add credibility and establish the ‘skilled artisan’ standard from a favorable perspective. An expert who testifies that they would not have expected the claimed compound to exhibit the reported activity \u2014 and can explain why, in technical terms \u2014 provides exactly the type of evidence that examiner skepticism about non-obviousness is designed to address.<\/p>\n\n\n\n

    Post-filing experimental data is generally accepted by the USPTO to support claims that were pending at the time of filing [22]. This means that applicants who file before all data is in hand \u2014 which is often necessary for priority date reasons \u2014 retain the ability to supplement the record with data generated during the prosecution period.<\/p>\n\n\n\n

    When to Appeal vs. When to Amend<\/strong><\/h3>\n\n\n\n

    After a final rejection, applicants face a strategic decision with long-term consequences: appeal to the Patent Trial and Appeal Board (PTAB) or continue prosecution through an RCE with claim amendments.<\/p>\n\n\n\n

    Appeals are more appropriate when the examiner’s legal position is genuinely wrong \u2014 when the cited prior art does not actually disclose a claim element, when the combination of references relied on for \u00a7 103 lacks a motivation to combine, or when the enablement rejection is inconsistent with the state of the art. PTAB reversals are more likely in \u00a7 102 cases than \u00a7 103 cases [16], which means appeals are tactically strongest when the rejection rests on a factual question (does this reference disclose this element?) rather than a legal\/factual judgment (is this combination obvious?).<\/p>\n\n\n\n

    RCEs with amendments are more appropriate when the examiner’s legal position has merit but the applicant can maintain commercially valuable claim scope through a targeted amendment. The prosecution history that results from amendment must be carefully managed: any limitation added to distinguish a reference becomes part of the prosecution history estoppel record and limits the doctrine of equivalents in subsequent infringement cases.<\/p>\n\n\n\n

    One option that is underutilized in pharmaceutical prosecution is a continuation application filed as an alternative to an RCE. A continuation can be filed with claims drafted to avoid the prior art identified in the parent’s prosecution history, without the prosecution history of the parent constraining the new claims in the same way. This requires careful management to avoid double patenting issues, but it provides strategic flexibility that pure RCE prosecution does not.<\/p>\n\n\n\n

    \n\n\n\n

    Addressing Specific Pharmaceutical Patent Categories<\/strong><\/h2>\n\n\n\n

    Formulation and Extended-Release Patents<\/strong><\/h3>\n\n\n\n

    Formulation patents \u2014 covering specific drug delivery systems, excipient combinations, release profiles, or dosage forms \u2014 occupy a legally complex middle ground between composition patents and method patents. They protect commercially important product features without protecting the API itself, making them both valuable (a competitor must match the formulation, not just the molecule) and vulnerable (formulation development is generally considered within the skill of the art).<\/p>\n\n\n\n

    The key to a defensible formulation patent is the ‘technical effect’ standard: the claimed formulation must provide a demonstrated technical advantage over prior art formulations that is not predictable from the prior art. Extended-release formulations that reduce dosing from three times daily to once daily, with pharmacokinetic data showing the sustained release profile, represent a genuine technical achievement [25]. Formulations that merely substitute one excipient for another functionally equivalent excipient, without a resulting performance advantage, do not.<\/p>\n\n\n\n

    When formulation patents are challenged on obviousness grounds \u2014 which they always are, by generic applicants filing ANDAs under the Hatch-Waxman Act \u2014 the decisive evidence is typically in vivo pharmacokinetic data. A formulation patent that can point to clinical PK data showing improved absorption, reduced variability, or enhanced bioavailability compared to the immediate-release formulation it replaces has a substantive non-obviousness case. A formulation patent that can only offer in vitro dissolution data is in a weaker position, because dissolution profiles in vitro do not always predict in vivo performance, and because in vitro optimization is generally considered within routine formulation science.<\/p>\n\n\n\n

    Biologic Drug Patents and the Biosimilar Challenge<\/strong><\/h3>\n\n\n\n

    The patent landscape for biologic drugs \u2014 monoclonal antibodies, fusion proteins, peptide therapeutics, gene therapies \u2014 is more complex than for small molecules, and the prosecution strategy for biologics must account for this complexity from the first filing decision.<\/p>\n\n\n\n

    Biologic patents typically cluster into several categories: composition patents covering the protein sequence and structure, manufacturing patents covering the production process and host cell systems, formulation patents covering the stabilized dosage form, and method of treatment patents covering specific patient populations and dosing regimens. Each category requires different prosecution strategy, and together they form the ‘patent thicket’ that biosimilar entrants must navigate under the Biologics Price Competition and Innovation Act (BPCIA) biosimilar approval framework.<\/p>\n\n\n\n

    The post-Amgen<\/em> environment for composition claims to antibody genera has already been discussed. The practical response is a portfolio-based approach: file narrow claims to characterized antibodies immediately, then file continuations as additional antibodies are generated and characterized. Manufacturing patents \u2014 claims directed to specific host cell lines, production conditions, purification methods, or glycosylation profiles \u2014 are less likely to face the breadth problems that afflict antibody genus claims, and they provide an important layer of protection that composition claims alone cannot cover.<\/p>\n\n\n\n

    Formulation patents for biologics are particularly valuable because biologic drug formulations are scientifically complex: the specific pH, buffer, excipient package, and container closure system that maintains protein stability at commercial scale involves genuine development effort that is not trivially reproducible. A formulation patent with data demonstrating that the claimed pH range and excipient combination is critical for stability \u2014 not merely adequate \u2014 is a meaningfully defensible asset.<\/p>\n\n\n\n

    Personalized Medicine and Diagnostic Method Patents<\/strong><\/h3>\n\n\n\n

    Precision oncology, pharmacogenomics, and companion diagnostics represent some of the fastest-growing areas of pharmaceutical innovation and some of the most legally challenging patent categories. The \u00a7 101 problem discussed earlier \u2014 the Mayo<\/em> framework’s hostility to claims that correlate a natural biological marker with a treatment decision \u2014 is the primary prosecution obstacle.<\/p>\n\n\n\n

    The prosecution strategies that have achieved the greatest \u00a7 101 success in diagnostic method cases share a common characteristic: they emphasize a specific technical improvement to the measurement process rather than the correlation itself. Claims that recite a novel assay technique, a specific sample preparation method, or a machine-learning classification algorithm with defined parameters have more \u00a7 101 survivability than claims that merely recite measuring a biomarker and using the result to guide treatment.<\/p>\n\n\n\n

    This is partly a drafting issue and partly a scientific development strategy. Companies building companion diagnostic programs should, from the beginning of the development program, be generating patent-relevant data not just on the clinical validity of the biomarker but on the specific technical method used to measure it. A proprietary assay platform, a novel sample stabilization method, or a validated bioinformatics pipeline all provide \u00a7 101-eligible subject matter on which to anchor the patent protection for the diagnostic use itself.<\/p>\n\n\n\n

    \n\n\n\n

    Part IV: Business and Strategic Implications<\/strong><\/h2>\n\n\n\n
    \n\n\n\n

    What Rejection Costs: The Business Case for Prosecution Investment<\/strong><\/h2>\n\n\n\n

    Prosecution Delay Is Market Life Lost<\/strong><\/h3>\n\n\n\n

    Every month that a pharmaceutical patent spends in prosecution without reaching allowance is a month subtracted from the effective commercial life of that patent. A drug that achieves FDA approval eight years after its composition patent was filed has, at most, twelve years of remaining patent protection \u2014 and that is before accounting for any generic challenge that might succeed in further shortening the exclusivity period through IPR or Hatch-Waxman litigation.<\/p>\n\n\n\n

    The financial arithmetic is not difficult. A branded drug generating $1 billion in annual revenue that loses two years of patent exclusivity due to prolonged prosecution \u2014 whether from poorly drafted claims requiring multiple rounds of rejection and amendment, or from an enablement challenge that required expensive continuation practice to resolve \u2014 has lost approximately $2 billion in protected revenue. Patent prosecution is not an overhead function. It is a revenue-generation function, and should be resourced accordingly.<\/p>\n\n\n\n

    Prosecution History Estoppel and the Long Shadow of Amendments<\/strong><\/h3>\n\n\n\n

    The amendments made during prosecution to overcome rejections create binding legal interpretations of the patent’s scope in subsequent infringement litigation. Under the doctrine of prosecution history estoppel, a patentee cannot assert infringement under the doctrine of equivalents against a claim element that was added or narrowed to distinguish prior art [43]. This principle means that every claim amendment in pharmaceutical prosecution should be analyzed not just for its effect on the examiner but for its effect on the claim scope available in future litigation.<\/p>\n\n\n\n

    The practical consequence: IP teams should insist that prosecution counsel document the strategic rationale for every amendment and argument made in response to an Office Action, and that the prosecution history be reviewed annually as part of the company’s patent portfolio assessment. A patent that was allowed as a result of claim narrowing that inadvertently created a design-around space for generic competitors is a weak asset regardless of its issuance date.<\/p>\n\n\n\n

    The R&D Pipeline Feedback Loop<\/strong><\/h3>\n\n\n\n

    Patent rejections \u2014 particularly rejections on novelty and obviousness grounds \u2014 create feedback effects on pharmaceutical R&D decisions that extend well beyond the individual application. When a structural class of compounds faces consistent obviousness rejections because the prior art in a therapeutic area is dense, a rational pharmaceutical company will redirect R&D resources toward areas with more favorable patent landscapes.<\/p>\n\n\n\n

    This is not merely a theoretical phenomenon. A Federal Trade Commission analysis documented that companies discard drugs from their R&D pipelines specifically because of weak patentability prospects [5]. Drugs with marginal patentability are less likely to attract the investment needed to complete development. The public health consequence \u2014 some number of potentially valuable medicines that are abandoned because the incentive structure doesn’t support their development \u2014 is an externality of the patent rejection system that policymakers debate, but that pharmaceutical R&D executives experience as a concrete portfolio management reality.<\/p>\n\n\n\n

    Using patent intelligence tools like DrugPatentWatch in the earliest stages of R&D target selection allows companies to assess the patent landscape before significant development investment is made. A program that looks scientifically promising but is entering a therapeutic area with 50 issued patents covering the relevant structural class faces a fundamentally different commercialization math than a program entering a patent-sparse area. Building that analysis into the go\/no-go decision criteria for early-stage programs is a practice that leading pharmaceutical companies have adopted and that smaller biotechs often neglect to their eventual cost.<\/p>\n\n\n\n

    Patent Term Extensions and Supplementary Protection Certificates<\/strong><\/h3>\n\n\n\n

    The Hatch-Waxman Act in the U.S. and equivalent legislation in Europe and Japan created Patent Term Extension (PTE) and Supplementary Protection Certificate (SPC) mechanisms specifically to compensate pharmaceutical innovators for the regulatory review time that consumes patent life [4]. In the U.S., a PTE can add up to five years to the term of a qualifying patent, with the extension calculated as half the time spent in IND clinical development plus the full time of regulatory review, minus any time the applicant failed to act with due diligence [69].<\/p>\n\n\n\n

    Approximately 40% of all U.S. PTE requests involve pharmaceutical patents [69]. The average extension granted has been approximately 2.5 years in the U.S., 3 years in the EU, and 2 years in Japan [69]. These numbers reflect the hard reality that the extensions only partially compensate for the patent life consumed by regulatory review \u2014 they do not restore the full term.<\/p>\n\n\n\n

    PTE applications have their own procedural requirements and filing deadlines. A PTE request must be filed within 60 days of FDA approval, and only one patent per approved product qualifies for extension at the USPTO [4]. Choosing which patent to extend \u2014 the composition patent, a formulation patent, or a method patent \u2014 requires analysis of which patent provides the broadest and most defensible market protection, informed by the patent portfolio structure and the likely generic entry strategy.<\/p>\n\n\n\n

    The existence of PTEs and SPCs also makes precise prosecution timeline management important. A patent that achieves allowance six months faster than its peers in the same prosecution pipeline has effectively gained six months of additional effective commercial life, because the PTE clock runs from the patent’s issue date to the FDA approval date, and a patent that issues closer to the approval date has a longer potential extension period.<\/p>\n\n\n\n

    \n\n\n\n

    Jurisdiction-Specific Nuances That Matter for Global IP Strategy<\/strong><\/h2>\n\n\n\n

    India: Section 3(d) and the Efficacy Standard<\/strong><\/h3>\n\n\n\n

    India’s Patent Act Section 3(d) bars patents on new forms of known substances \u2014 including polymorphs, salts, esters, and hydrates \u2014 unless the applicant demonstrates ‘significantly enhanced efficacy’ compared to the known substance [15]. The Novartis case established that bioavailability improvement does not equal efficacy improvement under this standard, and subsequent Indian Patent Office decisions have reinforced that the applicant must show a difference in therapeutic efficacy \u2014 typically through clinical data.<\/p>\n\n\n\n

    For pharmaceutical companies with significant markets in India, Section 3(d) means that a filing strategy built around polymorph, salt, or formulation patents requires either clinical data demonstrating enhanced therapeutic efficacy or an acceptance that these secondary patents will not provide meaningful protection in India. The strategic implication for global lifecycle management programs is that India requires a different analysis from the U.S. and Europe.<\/p>\n\n\n\n

    EPO: The Technical Effect Requirement and the Problem-Solution Approach<\/strong><\/h3>\n\n\n\n

    The EPO’s inventive step analysis \u2014 applied under Article 56 of the EPC \u2014 uses the problem-solution approach, which requires identifying the ‘objective technical problem’ that the claimed invention solves relative to the closest prior art, and then assessing whether the solution to that problem would have been obvious to a skilled person [14]. This framework is more structured than the U.S. obviousness analysis and creates specific prosecution opportunities for pharmaceutical applicants.<\/p>\n\n\n\n

    The key leverage point in EPO prosecution is the ‘technical effect’ requirement. If the claimed compound, formulation, or method provides a technical effect \u2014 a measurable improvement in a relevant property \u2014 relative to the closest prior art, the objective technical problem can be defined in terms of that effect, and the solution to that problem (the claimed invention) needs to be assessed against that specific problem. A narrow technical problem (achieving a specific stability improvement at a defined storage condition) is easier to defend as non-obvious than a broad one (making a better drug).<\/p>\n\n\n\n

    EPO prosecution counsel who understand the problem-solution approach can use it affirmatively: by defining the objective technical problem at the level of granularity that their experimental data best supports, they can make the inventive step case in terms most favorable to the applicant. This requires coordinating the prosecution argument with the underlying experimental data early in the prosecution process.<\/p>\n\n\n\n

    JPO: Experimental Data and the First-to-File Clock<\/strong><\/h3>\n\n\n\n

    Japanese pharmaceutical patent prosecution places particularly strong weight on experimental data demonstrating the claimed utility [24]. Applications for pharmaceutical compounds that lack pharmacological activity data face rejection on grounds that are essentially equivalent to the U.S. utility rejection, and the JPO’s standards for what constitutes sufficient activity data are applied with specificity.<\/p>\n\n\n\n

    Japan’s first-to-file system means that priority date management is critical. A filing delay that allows a competitor to file first \u2014 even by a day \u2014 can be dispositive in a patentability dispute. Given Japan’s role as a major pharmaceutical market and the significance of Japanese regulatory approval timelines for global product launches, Japanese patent prosecution should be planned as an integral part of the global filing strategy, not as an afterthought following U.S. and European filing decisions.<\/p>\n\n\n\n

    \n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n

    Novelty rejections are reversible but expensive to fight.<\/strong> More than 70% of \u00a7 102 rejections eventually result in allowance [16]. The most efficient path is an examiner interview (67.6% success rate [53]) combined with targeted claim amendment or compelling argument distinguishing the cited prior art. Allowing novelty rejections to drag through multiple rounds of RCEs erodes effective patent life without improving the strategic position.<\/p>\n\n\n\n

    Obviousness is the hardest ground to overcome without experimental data.<\/strong> Secondary considerations \u2014 unexpected results, long-felt need, commercial success \u2014 are the most reliable defense against \u00a7 103 rejections, but they require data generated before or during prosecution. The KSR<\/em>-era ‘obvious to try’ doctrine is particularly aggressive against incremental pharmaceutical innovations; the counter-argument requires showing either that the result was unpredictable or that the prior art actively discouraged the claimed approach.<\/p>\n\n\n\n

    Amgen v. Sanofi<\/em> changed the rules for broad biologics claims.<\/strong> Functional genus claims for antibodies, receptors, and enzyme inhibitors now require significantly more working examples than a pre-2023 portfolio strategy would have provided. Continuation practice \u2014 filing additional applications as more antibodies or variants are characterized \u2014 is the standard response.<\/p>\n\n\n\n

    The PTAB is a real threat, but Orange Book patents are relatively resilient.<\/strong> With a 70% all-claims invalidation rate for challenged claims overall [65], the PTAB is a serious post-grant risk. Orange Book pharmaceutical patents survive IPR at markedly higher rates (83% unscathed [66]), reflecting both the quality of prosecution and the intensity of defense investment. Build patent portfolios assuming they will face IPR.<\/p>\n\n\n\n

    Prosecution history is permanent.<\/strong> Every amendment, every argument, every interview summary becomes part of the prosecution history record that limits claim scope in litigation. Treat each prosecution decision as a litigation strategy decision, and document the strategic rationale for every substantive response to an Office Action.<\/p>\n\n\n\n

    Patent intelligence is a prosecution input, not just a competitive monitoring tool.<\/strong> Platforms like DrugPatentWatch enable pre-filing landscape analysis that identifies white space, maps competitor prosecution histories, and tracks patent expirations in real time. Using this intelligence in drafting decisions \u2014 before the application is filed \u2014 produces more defensible claims than any amount of reactive prosecution can achieve.<\/p>\n\n\n\n

    Patent term extensions only partially compensate for regulatory delay.<\/strong> With average U.S. extensions of approximately 2.5 years on a 20-year nominal term [69], and with development timelines consuming 8 to 12 years before approval, the effective commercial life of a pharmaceutical patent is far shorter than its nominal term. Every month saved in prosecution directly adds to commercial exclusivity.<\/p>\n\n\n\n

    Jurisdiction differences are material.<\/strong> An India filing strategy that relies on polymorph or formulation patents without clinical efficacy data will fail under Section 3(d). An EPO strategy that does not address the technical effect relative to the closest prior art is underprepared for inventive step examination. A JPO strategy without pharmacological activity data faces utility rejection. Global pharmaceutical patent programs require jurisdiction-specific prosecution strategies from the first filing decision.<\/p>\n\n\n\n

    \n\n\n\n

    FAQ<\/strong><\/h2>\n\n\n\n

    Q1: My pharmaceutical compound is structurally analogous to a known drug in the prior art. Can I still get a composition patent?<\/strong><\/p>\n\n\n\n

    Structural analogy to a prior art compound does not automatically preclude patentability, but it substantially raises the prosecution bar. A compound that differs from a known drug by a single substituent or stereocenter will face a strong obviousness presumption unless the applicant can demonstrate that the claimed compound exhibits unexpected properties \u2014 meaningfully different potency, selectivity, safety profile, or pharmacokinetic behavior \u2014 that the prior art compound does not show. The key is comparative experimental data: side-by-side testing of the claimed compound and the closest prior art compound under identical conditions, showing a difference that a skilled medicinal chemist would not have predicted from the structural similarity. Without that data, the prosecution outcome is difficult to predict and the resulting patent, even if allowed, is vulnerable in post-grant challenge proceedings.<\/p>\n\n\n\n

    Q2: We received a final rejection. Is the prosecution effectively over?<\/strong><\/p>\n\n\n\n

    A final rejection is not a terminus. It is a specific procedural status that limits, but does not eliminate, your options. You can file a Request for Continued Examination (RCE) with amended claims and new arguments, pursue an after-final amendment under 37 CFR 1.116, request an examiner interview after final rejection (which examiners are not required to grant but frequently do for meritorious cases), or file a notice of appeal to the PTAB. The data showing that 48% of final-rejected applications issued as patents within one year [59] reflects the genuine viability of post-final prosecution. What a final rejection should trigger is a rigorous strategic review: is the current claim scope worth fighting for, or should the prosecution strategy pivot to claims with a clearer path to allowance?<\/p>\n\n\n\n

    Q3: How does the Amgen v. Sanofi decision affect drug discovery programs in earlier stages of development, before antibody candidates have been fully characterized?<\/strong><\/p>\n\n\n\n

    The practical answer is that Amgen<\/em> makes the timing and scope of biologic patent applications more consequential than ever. For early-stage programs with only a few characterized antibodies, filing broad functional genus claims now carries a high risk of enablement rejection under the Amgen<\/em> standard. The recommended approach is to file claims at the scope actually enabled by the data available at filing \u2014 specific characterized antibodies with defined sequences and functional data \u2014 and use continuation applications to expand scope as the program generates additional characterized candidates. Building in a structured process for regular continuation filings tied to clinical and preclinical development milestones is now a standard element of best-in-class biologic IP strategy.<\/p>\n\n\n\n

    Q4: How should generic drug companies and biosimilar developers use pharmaceutical patent data to identify and time market entry?<\/strong><\/p>\n\n\n\n

    This is precisely the use case that drives a significant portion of pharmaceutical patent intelligence activity. Generic and biosimilar developers typically use patent expiration data, Orange Book listings, and prosecution history analysis to identify when specific patents protecting a branded product are likely to expire or be vulnerable to invalidity challenge. DrugPatentWatch provides expiration tracking, Orange Book data, and patent prosecution history analysis that allows generics and biosimilar teams to assess the strength of a patent thicket around a specific product \u2014 including identifying which patents are likely IPR candidates and which have prosecution histories that might limit their scope in litigation. The goal is to optimize the timing of ANDA or biosimilar BLA filings and, where appropriate, to identify the most strategically efficient IPR challenge targets.<\/p>\n\n\n\n

    Q5: Can a drug patent be saved after a court finds it invalid, or is invalidity always a permanent outcome?<\/strong><\/p>\n\n\n\n

    In the U.S. litigation system, a finding of invalidity at the district court level can be appealed to the Federal Circuit, and Federal Circuit decisions can in theory be appealed to the Supreme Court \u2014 though the Court takes only a small fraction of patent cases for review. In parallel PTAB proceedings, a final written decision invalidating claims can also be appealed to the Federal Circuit. The statistics on appeal success are not encouraging for patentees: PTAB final written decisions are affirmed by the Federal Circuit at high rates. The more practical ‘salvation’ mechanism is the continuation strategy discussed throughout this article \u2014 maintaining a family of continuation applications with claims at varying scope levels means that even if a lead patent is invalidated, related continuation claims may survive. Portfolio management that treats each patent as one layer of a multi-layered defense structure is far more resilient than single-patent dependence.<\/p>\n\n\n\n

    \n\n\n\n

    References<\/strong><\/h2>\n\n\n\n

    [1] Number Analytics. (2025). Pharmaceutical Patents: A Comprehensive Guide<\/em>. https:\/\/www.numberanalytics.com\/blog\/ultimate-guide-pharmaceutical-patents-patent-eligibility<\/p>\n\n\n\n

    [2] American Journal of Managed Care. (n.d.). How Drug Life-Cycle Management Patent Strategies May Impact Formulary Management<\/em>. https:\/\/www.ajmc.com\/view\/a636-article<\/p>\n\n\n\n

    [3] DrugPatentWatch. (2025). Best Practices for Drug Patent Portfolio Management: Leveraging Patent Data for Competitive Advantage<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/best-practices-for-drug-patent-portfolio-management-2\/<\/p>\n\n\n\n

    [4] DrugPatentWatch. (2024). Filing Strategies for Maximizing Pharma Patents: A Comprehensive Guide for Business Professionals<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/filing-strategies-for-maximizing-pharma-patents\/<\/p>\n\n\n\n

    [5] Federal Trade Commission. (n.d.). Unpatentable Drugs and the Standards of Patentability<\/em>. https:\/\/www.ftc.gov\/sites\/default\/files\/documents\/public_comments\/emerging-health-care-competition-and-consumer-issues-537778-00055\/537778-00055.pdf<\/p>\n\n\n\n

    [8] Arapacke Law Group. (n.d.). Patentability Meaning: An Easy Guide to Essential Requirements<\/em>. https:\/\/arapackelaw.com\/patents\/patentability-meaning\/<\/p>\n\n\n\n

    [12] Lumenci. (2025). Understanding Prior Art Search in 2025<\/em>. https:\/\/lumenci.com\/blogs\/prior-art-search-guide-patent-non-patent-literature\/<\/p>\n\n\n\n

    [14] J A Kemp. (n.d.). Patenting Polymorphs at the European Patent Office<\/em>. https:\/\/www.jakemp.com\/knowledge-hub\/patenting-polymorphs-at-the-european-patent-office\/<\/p>\n\n\n\n

    [15] Wikipedia. (n.d.). Novartis v. Union of India & Others<\/em>. https:\/\/en.wikipedia.org\/wiki\/Novartis_v.Union_of_India<\/em>%26_Others<\/p>\n\n\n\n

    [16] AccelerateIP. (n.d.). 35 USC 102 Patent Rejection: Understanding Anticipation<\/em>. https:\/\/accelerateip.com\/35-usc-102-patent-rejection-understanding-anticipation\/<\/p>\n\n\n\n

    [19] PMC. (2015). What Is Your Reasonable Expectation of Success in Obtaining Pharmaceutical or Biotechnology Patents Having Nonobvious Claimed Inventions That the Courts Will Uphold?<\/em> https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4382726\/<\/p>\n\n\n\n

    [21] PMC. (2014). Identification of the Factors That Result in Obviousness Rulings for Biotech Patents: An Updated Analysis of the US Federal Circuit Decisions After KSR<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3981861\/<\/p>\n\n\n\n

    [22] USPTO. (n.d.). 716 \u2014 Affidavits or Declarations Under 37 CFR 1.132 and Other Evidence Traversing Rejections<\/em>. https:\/\/www.uspto.gov\/web\/offices\/pac\/mpep\/s716.html<\/p>\n\n\n\n

    [24] Tandfonline. (2015). Preparing Effective Experimental Data for Pharmaceutical Patent Applications From US and Japanese Perspectives<\/em>. https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa.14.38<\/p>\n\n\n\n

    [25] D Young & Co. (2013). Pharmaceutical Patenting<\/em>. https:\/\/www.dyoung.com\/en\/knowledgebank\/articles\/pharmaceuticalpatenting0213<\/p>\n\n\n\n

    [27] DLA Piper. (2025). The Federal Circuit Upholds Drug Dosing Regimen as Valid and Nonobvious<\/em>. https:\/\/www.dlapiper.com\/insights\/publications\/synthesis\/2025\/the-federal-circuit-upholds-drug-dosing-regimen-as-valid-and-nonobvious<\/p>\n\n\n\n

    [28] PMC. (2016). Extending the Market Exclusivity of Therapeutic Antibodies Through Dosage Patents<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4968089\/<\/p>\n\n\n\n

    [31] DrugPatentWatch. (n.d.). Key Strategies for Successfully Challenging a Drug Patent<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/key-strategies-for-successfully-challenging-a-drug-patent\/<\/p>\n\n\n\n

    [32] Cooley LLP. (2025). Precedential Federal Circuit Decision Overturns Lack of Written Description Based on Later-Discovered Technology<\/em>. https:\/\/www.cooley.com\/news\/insight\/2025\/2025-01-21-precedential-federal-circuit-decision-overturns-lack-of-written-description-based-on-later-discovered-technology<\/p>\n\n\n\n

    [33] USPTO. (n.d.). 2163 \u2014 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) Written Description Requirement<\/em>. https:\/\/www.uspto.gov\/web\/offices\/pac\/mpep\/s2163.html<\/p>\n\n\n\n

    [35] USPTO. (n.d.). 2164 \u2014 The Enablement Requirement<\/em>. https:\/\/www.uspto.gov\/web\/offices\/pac\/mpep\/s2164.html<\/p>\n\n\n\n

    [36] Cleary IP Tech Insights. (2023). U.S. Supreme Court Clarifies Enablement for Functional Claims in Amgen v. Sanofi<\/em>. https:\/\/www.clearyiptechinsights.com\/2023\/05\/u-s-supreme-court-clarifies-enablement-for-functional-claims-in-amgen-v-sanofi\/<\/p>\n\n\n\n

    [38] Drug Discovery News. (n.d.). Commentary: Federal Circuit Enforces Written Description Requirement Even for Negative Limitations and Narrower Claims<\/em>. https:\/\/www.drugdiscoverynews.com\/commentary-federal-circuit-enforces-written-description-requirement-even-for-negative-limitations-and-narrower-clai-8035<\/p>\n\n\n\n

    [41] PatentPC. (n.d.). AI Patent Rejections Stats: What Percentage of AI Patents Get Denied?<\/em> https:\/\/patentpc.com\/blog\/ai-patent-rejections-stats-what-percentage-of-ai-patents-get-denied<\/p>\n\n\n\n

    [43] LexisNexis IP. (n.d.). Drafting Quality Patents to Avoid \u00a7 112 Rejections<\/em>. https:\/\/www.lexisnexisip.com\/resources\/drafting-quality-patents-to-avoid-%C2%A7112-rejections\/<\/p>\n\n\n\n

    [44] IPWatchdog. (2017). \u00a7 112 Rejections: Where They Are Found and How Applicants Handle Them<\/em>. https:\/\/ipwatchdog.com\/2017\/05\/09\/112-rejections-applicants-handle\/id=82668\/<\/p>\n\n\n\n

    [53] IPWatchdog. (2017). How to Respond to a \u00a7 102 Rejection<\/em>. https:\/\/ipwatchdog.com\/2017\/04\/06\/respond-102-rejection\/id=81585\/<\/p>\n\n\n\n

    [54] USPTO. (n.d.). 713 \u2014 Interviews<\/em>. https:\/\/www.uspto.gov\/web\/offices\/pac\/mpep\/s713.html<\/p>\n\n\n\n

    [58] PatentlyO. (2024). USPTO Patent Grant Rate and Growing Backlog<\/em>. https:\/\/patentlyo.com\/patent\/2024\/11\/uspto-patent-grant.html<\/p>\n\n\n\n

    [59] PatentlyO. (2025). Patent Applications After Final Rejection: A One-Year Follow-Up Study<\/em>. https:\/\/patentlyo.com\/patent\/2025\/02\/patent-applications-rejection.html<\/p>\n\n\n\n

    [60] PatentPC. (2024). European Patent Office Statistics: Key Insights for 2024<\/em>. https:\/\/patentpc.com\/blog\/european-patent-office-statistics-key-insights-for-2024<\/p>\n\n\n\n

    [62] Seiwa Patent & Law. (2023). IP Statistics 2023<\/em>. https:\/\/www.seiwapat.jp\/en_ip\/.assets\/IP_News_EN.230414.IP_Statistics_April_2023.pdf<\/p>\n\n\n\n

    [63] EPO. (2021). IP5 Statistics Report 2021 Edition<\/em>. https:\/\/link.epo.org\/ip5\/IP5%20Statistics%20Report%202021_1.pdf<\/p>\n\n\n\n

    [64] Abe, Ikubo & Katayama. (2024). JPO Published the Annual Report 2024<\/em>. https:\/\/www.aiklaw.co.jp\/en\/whatsnewip\/2024\/08\/26\/5002\/<\/p>\n\n\n\n

    [65] IPWatchdog. (2025). The PTAB’s 70% All-Claims Invalidation Rate Continues to Be a Source of Concern<\/em>. https:\/\/ipwatchdog.com\/2025\/01\/12\/ptab-70-claims-invalidation-rate-continues-source-concern\/id=184956\/<\/p>\n\n\n\n

    [66] JDSupra \/ Troutman Pepper Locke. (n.d.). Why Biotech and Pharma Patents Survive IPR<\/em>. https:\/\/www.jdsupra.com\/legalnews\/why-biotech-and-pharma-patents-survive-41420\/<\/p>\n\n\n\n

    [69] PatentPC. (n.d.). Patent Term Extension Statistics: What Innovators Need to Know<\/em>. https:\/\/patentpc.com\/blog\/patent-term-extension-statistics-what-innovators-need-to-know<\/p>\n","protected":false},"excerpt":{"rendered":"

    How to diagnose the six most common grounds for pharmaceutical patent rejection \u2014 and the prosecution strategies that actually reverse […]<\/p>\n","protected":false},"author":1,"featured_media":25156,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-23879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=23879"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23879\/revisions"}],"predecessor-version":[{"id":37929,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23879\/revisions\/37929"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/25156"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=23879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=23879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=23879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}